Concall Intelligence
Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.
Management evidence
Generated 22 Oct, 9:13 am IST · click a summary to inspect source-linked evidence for this results quarter.
| Company | Call and sources | Reported result | Management outlook | Evidence-led conclusion | Review |
|---|---|---|---|---|---|
| INDIAGLYCO India Glycols Limited FMCG · Micro | Sep 2026 10 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call No measurable guidance | India Glycols delivered a strong Q1 FY27 with double-digit growth in gross revenue, EBITDA, and PAT, alongside steady progress on its NCLT-approved business restructuring into separate entities. Evidence summary ready | |
| BANSALWIRE Bansal Wire Industries Limited Industrials · Small | Sep 2026 10 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance raised | Bansal Wire Industries Limited reported a strong financial year for FY2025-26 with consolidated revenue growing 19% to Rs 4,160 crore, EBITDA up 17% to Rs 324 crore, and PAT rising 10% to Rs 161 crore, backed by record volumes of 4,58,000 tonnes. Management remains optimistic about sustainable growth driven by capacity expansion at Dadri, scaling of high-margin specialty and B2C segments, and improved cash generation. Evidence summary ready | |
| MANINDS Man Industries (India) Limited Industrials · Small | Sep 2026 10 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Man Industries reported robust performance in Q1 FY27 with consolidated EBITDA reaching a record INR155 crores (up 92.6% YoY) and stand-alone PAT more than doubling YoY, driven by optimized product and geographic mix. Management maintains an optimistic outlook underpinned by a structural multiyear demand cycle across MENA, GCC, and Southeast Asia, along with strategic capacity additions in Saudi Arabia (NPC acquisition, Dammam coating facility) and Jammu (stainless steel proj Evidence summary ready | |
| COCHINSHIP Cochin Shipyard Limited Industrials · Mid | Sep 2026 10 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Cochin Shipyard reported stable performance for Q1 FY27 with a turnover of INR 1,094.21 crores, PBT of INR 202.49 crores, and PAT of INR 151.45 crores. Management maintains a positive long-term growth outlook supported by a robust order book of INR 22,000 crores, expansion into ship repair and hybrid shipbuilding facilities, and strategic international partnerships despite execution dependencies and working capital pressures. Evidence summary ready | |
| KARAMTARA Karamtara Engineering Limited Industrials · Micro | Sept 2026 9 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Karamtara Engineering Limited delivered a strong first quarterly performance as a listed company for Q1 FY27, reporting 72% YoY revenue growth to INR1,581 crores and 45% YoY PAT growth to INR87 crores, driven by robust renewable demand and international expansion. Evidence summary ready | |
| WABAG VA Tech Wabag Limited Infra · Micro | Sept 2026 7 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | VA Tech Wabag reported record FY 2025-26 performance with revenue of INR 3,944 Crores, EBITDA of INR 524 Crores, and PAT of INR 371 Crores, supported by a robust order book exceeding INR 17,200 Crores and a net cash positive position for the sixth consecutive year. Evidence summary ready | |
| METROBRAND Metro Brands Limited Consumer · Small | Sept 2026 5 Oct 2026 Transcript verified | Good 55/100 | Optimistic outlook No comparable prior call No measurable guidance | Metro Brands Limited reported steady operational performance for FY25-26, crossing the 1,000-store milestone and posting double-digit revenue and PAT growth, though shareholders raised concerns regarding a decline in revenue per square foot and return on capital employed. Evidence summary ready | |
| ALLCARGO Allcargo Logistics Limited Services · Small | Sept 2026 3 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Allcargo Logistics reported a purposeful transformation year in FY2025-26, integrating express distribution and contract logistics under Vision 2030, resulting in revenue of INR 2,058 crores and a 16% growth in EBITDA to INR 233 crores. Evidence summary ready | |
| PAKKA PAKKA LIMITED Industrials · Small | Sept 2026 2 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Pakka Limited held its 46th AGM reflecting on a demanding FY 2025-26 marked by operational shutdowns, equipment breakdowns, project delays, and lower earnings, while pointing to an improving June quarter and ongoing progress on Project Jagriti for long-term growth. Evidence summary ready | |
| SYMBIOTEC Symbiotec Pharmalab Limited Pharma · Micro | Sep 2026 2 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call Guidance maintained | Symbiotec Pharmalab reported Q1 FY27 consolidated revenue of INR 218 crores (up 7% YoY), driven mainly by the stable steroid API business. However, consolidated net profit stood lower at INR 14 crores due to a significant operational expense drag of INR 23 crores and depreciation of INR 11 crores from recently invested new businesses (biotech CDMO and complex injectables) where commercial revenues are yet to commence. Management maintains a confident revenue and EBITDA growth Evidence summary ready |